Semaglutide and Tirzepatide Significantly Reduce Worsening Heart Failure Events in HFmrEF/HFpEF Patients within 6 Months
Background
Heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF) are debilitating conditions often linked to obesity and metabolic dysfunction. Current therapeutic options for these adiposity-related forms of heart failure are limited, leaving a significant gap in patient care. Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists, have shown promise in improving cardiovascular outcomes, but the precise timeline for these clinical benefits has remained unclear.
Study Design
This systematic review and meta-analysis searched PubMed, Embase, and CENTRAL until July 12, 2025, for randomized controlled trials (RCTs) of incretin-based therapies (semaglutide, tirzepatide) in adults with overweight/obesity and HF (ejection fraction >40%) with at least 52-week follow-up. Researchers extracted study-level data and reconstructed individual participant data (IPD). Time to benefit was estimated by iteratively calculating hazard ratios (HR) and 95% confidence intervals (CI) with the dataset truncated for each day of follow-up. Overall results were pooled using reconstructed IPD and study-level random-effects meta-analyses. Risk of bias was assessed with RoB 2 and certainty of evidence with GRADE.
Results
Four trials, encompassing 4149 participants with a weighted average median follow-up of 2.47 years, were included, showing low risk of bias. Compared to placebo, incretin-based therapies significantly reduced the composite endpoint of worsening HF or cardiovascular death by 41% (HR 0.59, 95% CI 0.45-0.78; moderate certainty). The nominal time to first statistical significance for this composite outcome was 126 days (4.1 months), with sustained significance observed after day 162 (5.3 months).
Key Findings
- Incretin-based therapies reduced worsening HF or cardiovascular death by 41% (HR 0.59, 95% CI 0.45-0.78).
- Statistical significance for the composite endpoint was first observed at 126 days (4.1 months).
- Sustained statistical significance for the composite endpoint was achieved after day 162 (5.3 months).
- Worsening HF events alone were reduced by 67% (HR 0.33, 95% CI 0.20-0.54).
- Sustained statistical significance for worsening HF events was observed after day 183 (6.0 months).
Why It Matters
This meta-analysis provides crucial insights into the timeline of cardiovascular benefits from incretin-based therapies in obesity-related HFmrEF/HFpEF. Patients can expect to see statistically significant reductions in worsening heart failure events within approximately 6 months of starting treatment with semaglutide or tirzepatide. This rapid onset of sustained benefit highlights the potential for these peptides to become a cornerstone therapy, shifting the paradigm from solely glycemic control to comprehensive cardiometabolic disease modification. For clinicians and biohackers, this suggests that early and consistent adherence to incretin-based protocols is vital for realizing their full cardiovascular protective effects in this vulnerable population.
semaglutide
tirzepatide
heart-failure
hfpef
hfmref
obesity